AGIO - アギオス・ファ―マシュ―ティカルズ （Agios Pharmaceuticals Inc.） アギオス・ファ―マシュ―ティカルズAGIOのチャート
AGIOの企業情報
| symbol | AGIO |
|---|---|
| 会社名 | Agios Pharmaceuticals Inc （アギオス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アジオス・ファーマスーティカルズ(Agios Pharmaceuticals Inc.)はバイオ医薬品会社。同社は根本的に癌と先天性代謝異常(IEM)の治療法を変えるために代謝に対する深い理解と代謝酵素を阻害･活性化できる薬剤を開発する能力を結合して応用しようとする。同社はすでに癌と先天性代謝異常に対して新薬開発の目標を明確･有効にした。同社の2つの進んだ癌プログラムは「IDH1」と「IDH2」と呼ばれるイソクエン酸脱水素酵素1と2の変異を標的とする。同社の薬剤候補は他の細胞に見られるIDH1とIDH2の正常形態に対し、癌に見られるIDH1とIDH2の変異形態を特定する。 アギオス・ファ―マシュ―ティカルズは、がん代謝と先天性代謝異常の分野に特化した米国のバイオ医薬品企業。主製品候補は、変異型イソクエン酸脱水素酵素2｢AG-221｣及びイソクエン酸デヒドロゲナ―ゼ1｢AG-120｣。急性骨髄性白血病などの突然変異IDH2を保有する癌または、突然変異IDH1を保有する癌患者用の強力な阻害剤。 at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible |
| 本社所在地 | 88 Sidney Street Cambridge MA 02139 USA |
| 代表者氏名 | David P. Schenkein David P. Schenkein |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 617-649-8600 |
| 設立年月日 | 39295 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 382人 |
| url | www.agios.com |
| nasdaq_url | https://www.nasdaq.com/symbol/agio |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -329.37600 |
| 終値（lastsale） | 68.07 |
| 時価総額（marketcap） | 3947554648.32 |
| 時価総額 | 時価総額（百万ドル） 3819.391 |
| 売上高 | 売上高（百万ドル） 70.33300 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3102.486 |
| 当期純利益 | 当期純利益（百万ドル） -324.99200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Agios Pharmaceuticals Inc revenues increased from $21.9M to $49.2M. Net loss increased 7% to $159.6M. Revenues reflect Collaboration revenue - related party increase of 54% to $33.7M. Higher net loss reflects Research and development increase of 15% to $146.6M (expense) General and administrative increase of 66% to $38.5M (expense). |
AGIOのテクニカル分析
AGIOのニュース
Agios Pharmaceuticals: Good Execution, A Good Deal Of Cash, Some Hurdles 2023/05/24 15:02:18 Seeking Alpha
Agios Pharmaceuticals done well after its pivot to rare diseases. Click here for more on AGIO stock.
Agios Pharmaceuticals''s Return On Capital Employed Overview 2023/05/15 14:47:00 Benzinga
Benzinga Pro data, Agios Pharmaceuticals (NASDAQ: AGIO ) reported Q1 sales of $5.61 million. Earnings fell to a loss of $81.02 million, resulting in a 321.81% decrease from last quarter. In Q4, Agios Pharmaceuticals earned $36.53 million and total sales reached $4.31 million. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
The BWB Awards at Biotech Week Boston Returns for a Celebratory Gala September 18th, 2023 2023/05/10 17:30:00 Accesswire
BOSTON, MA / ACCESSWIRE / May 10, 2023 / The BWB Awards at Biotech Week Boston returns for a night of dinner, drinks, entertainment, and the recognition of the top individuals, companies, and organizations in the life sciences community. Since 2018, the Awards at the Biotech Week Boston festival have been bringing together the faces and names that make the Boston community the beating heart of the biotech world. Join 150+ leaders across the entire life science spectrum at the BWB Awards 2023. About the BWB Awards: Nominations are now open to honor what makes the life sciences ecosystem vibrant and innovative. Submit by May 19 th . Nomination categories include: START-UP OF THE YEAR - The Start-up of the Year award recognizes a burgeoning company that has blossomed into an industry leader through growth and innovation. DE&I INITIATIVE - The DE&I Initiative award recognizes an organization or group that has advanced diversity, equity, and inclusion in the workplace by championing the perspectives and contributions of employees representing marginalized groups.
Agios Pharmaceuticals, Inc. (AGIO) Q1 2023 Earnings Call Transcript 2023/05/04 16:42:04 Seeking Alpha
Agios Pharmaceuticals, Inc. (NASDAQ:NASDAQ:AGIO) Q1 2023 Earnings Conference Call May 4, 2023 8:00 AM ETCompany ParticipantsCecilia Jones – Chief Financial OfficerBrian Goff – Chief…
Agios Pharmaceuticals, Inc. 2023 Q1 - Results - Earnings Call Presentation 2023/05/04 14:44:27 Seeking Alpha
The following slide deck was published by Agios Pharmaceuticals, Inc.
How did Agios Pharmaceuticals Inc. (AGIO) fare last session? 2023/02/24 15:54:00 US Post News
The share price of Agios Pharmaceuticals Inc. (NASDAQ:AGIO) fell to $26.06 per share on Thursday from $26.52. While Agios Pharmaceuticals Inc. has underperformed by -1.73%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO fell by -9.70%, with highs and lows ranging from $34.76 to $16.75, […]
Agios Pharmaceuticals, Inc. (AGIO) Q4 2022 Earnings Call Transcript 2023/02/23 16:35:35 Seeking Alpha
Agios Pharmaceuticals, Inc. (NASDAQ:NASDAQ:AGIO) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ETCompany ParticipantsJessi Rennekamp - Senior Director, Corporate…
Agios Pharmaceuticals GAAP EPS of -$4.23 beats by $2.06, revenue of $14.24M beats by $0.35M (NASDAQ:AGIO) 2023/02/23 12:12:31 Seeking Alpha
Agios Pharmaceuticals press release (AGIO): FY GAAP EPS of -$4.23 beats by $2.06.Revenue of $14.24M beats by $0.35M.$1.1 Billion of Cash, Cash Equivalents and Marketable Securities…
Agios Pharma: Multiple Growth Catalysts If Pyrukynd Conversions Pull Through 2023/02/22 12:10:16 Seeking Alpha
Agios Pharmaceuticals is looking to expand indications for the label into secondary conditions such as sickle cell disease. See why AGIO stock is a Hold now.
Nasdaq - Agios Pharmaceuticals to Release Quarterly Earnings on Thursday 2023/02/16 07:35:15 Business Mag
Agios Pharmaceuticals will release its earnings data before the market opens on Thursday, February 23rd. Analysts expect Agios Pharmaceuticals to post earnings of per share for…
Investing in Agios Pharmaceuticals Inc. (AGIO) might be an excellent idea, but the stock is currently overvalued/undervalued 2023/01/26 16:00:00 US Post News
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) marked $30.78 per share on Wednesday, up from a previous closing price of $29.75. While Agios Pharmaceuticals Inc. has overperformed by 3.46%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGIO fell by -1.25%, with highs and lows ranging from $34.76 to […]
Agios Pharmaceuticals (AGIO) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:AGIO) 2023/01/11 18:56:28 Seeking Alpha
The following slide deck was published by Agios Pharmaceuticals, Inc.
Agios Unveils 2023-2026 Value-driving Catalysts Enabling Company''s Vision to Transform Patient Outcomes in Rare Diseases 2023/01/09 01:00:00 Benzinga
– Consistent and compelling clinical data across rare hematological diseases support five ongoing pivotal trials in thalassemia, sickle cell disease and pediatric pyruvate kinase (PK) deficiency – – Driving toward two additional PYRUKYND ® indications, with potential FDA approvals in thalassemia in 2025 and sickle cell disease in 2026 – – Strong cash position expected to enable completion of ongoing programs and pipeline expansion to cash-flow positivity – CAMBRIDGE, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced its anticipated 2023 milestones and significant value-driving catalysts through 2026 that support the company''s mission to transform patient outcomes in rare diseases. Agios will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023, at 7:30 a.m. PT, and a live webcast will be available at investor.agios.com . "Agios is poised for significant growth with the potential for approvals in two additional PYRUKYND ® indications by 2026, and is well capitalized to advance its robust existing clinical pipeline and expand its portfolio within our core areas of expertise," said Brian Goff, chief executive officer at Agios. "As the pioneering leader in PK activation with more than seven years of clinical experience with PYRUKYND ® , we have generated an impressive body of consistent and compelling data across rare hematological diseases with shared underlying pathophysiology that further builds confidence in our five ongoing pivotal clinical trials in thalassemia, sickle cell disease and pediatric PK deficiency.
Agios Pharmaceuticals Inc. (NASDAQ: AGIO): Is It Stable And Growing? 2022/12/31 14:00:00 Stocks Register
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) shares, rose in value on Friday, 12/30/22, with the stock price up by 2.41% to the previous day’s close as strong demand from buyers drove the stock to $28.08. Actively observing the price movement in the last trading, the stock closed the session at $27.42, falling within a range of $26.88 … Agios Pharmaceuticals Inc. (NASDAQ: AGIO): Is It Stable And Growing? Read More »
Analysts Predicting A Spike In Agios Pharmaceuticals Inc. (NASDAQ: AGIO)? 2022/12/24 17:00:00 Stocks Register
Agios Pharmaceuticals Inc. (NASDAQ:AGIO) price on Friday, December 23, fall -5.09% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $27.03. A look at the stock’s price movement, the close in the last trading session was $28.48, moving within a range at $26.80 and $28.42. The beta value … Analysts Predicting A Spike In Agios Pharmaceuticals Inc. (NASDAQ: AGIO)? Read More »